Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients - Trial NCT06386679
Access comprehensive clinical trial information for NCT06386679 through Pure Global AI's free database. This Phase 1 trial is sponsored by Siriraj Hospital and is currently Enrolling by invitation. The study focuses on Knee Osteoarthritis. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Siriraj Hospital
Timeline & Enrollment
Phase 1
Aug 17, 2023
Mar 01, 2025
Primary Outcome
Incidence of abnormal physical examination,Incidence of abnormal vital sign,Incidence of abnormal laboratory test results,Incidence of abnormal ECG parameters,The type of Adverse event (AE), numbers of AE and proportion of patients with AE.
Summary
Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to
 treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces
 inflammation and promotes the recovery of knee function, leading to an improved quality of
 life.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06386679
Non-Device Trial